Xcout Intel
Akero Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Akero Therapeutics, Inc. among biotech companies — ranked by similarity to what Akero Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Akero Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Akero Therapeutics, Inc.
Akero Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company is dedicated to developing transformational therapies for metabolic dysfunction-associated steatohepatitis and other metabolic diseases.
Akero Therapeutics, Inc. at a glance
Akero Therapeutics, Inc. is a biotech company. Its most recent funding round raised $45.5M in December 2018. Xcout tracks 15 named people at Akero Therapeutics, Inc., including Andrew Cheng (President). Xcout recorded 5 job postings from Akero Therapeutics, Inc. in the last 90 days.
Akero Therapeutics, Inc. leadership
- Andrew ChengPresident
- Tom RossSenior Vice President, General Counsel
- Mark IwickiChairman
- Jonathan YoungChief Executive Officer
- Dominick VillaniVice President, Quality
- Libette LuceVice President, Regulatory Affairs
9 more named people on record for Akero Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Akero Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $45.5M | — | |
| Series B | $70M | — | |
| Series A | $65M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Akero Therapeutics, Inc.
Xcout recorded 5 job postings from Akero Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see Akero Therapeutics, Inc.'s hiring signals →
Top 12 Akero Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Akero Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Carmot Therapeutics, Inc. is a biopharmaceutical company headquartered in Berkeley, California, focused on discovering and developing innovative treatments for metabolic diseases and obesity.
Similar biotech company
89bio is a clinical-stage biopharmaceutical company that develops innovative therapies for patients with liver and cardiometabolic diseases. The company utilizes its expertise in FGF21 as a master metabolic regulator to create treatments, such as pegozafermin, for conditions with limited or no approved therapeutic options.
Biotechnology
Metacrine, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company builds a pipeline of differentiated therapies targeted at treating liver and gastrointestinal diseases.
Similar biotech company
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
Similar biotech company
Marea Therapeutics is a biotechnology research company headquartered in South San Francisco, California. The company focuses on developing novel therapeutics within the biopharma sector.
Similar biotech company
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to developing innovative therapies for metabolic and endocrine disorders. Its flagship product candidate, VK2809, is an orally administered, tissue- and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). Currently, VK2809 is undergoing Phase IIb clinical trials to address non-alcoholic steatohepatitis (NASH) confirmed by biopsy, as well as non-alcoholic fatty liver disease (NAFLD). The company's pipeline further features VK5211, an orally available non-steroidal selective androgen receptor modulator, which is in Phase II trials for patients convalescing from non-elective hip fracture surgery. Additionally, VK0612, an oral candidate poised for Phase IIb evaluation, targets type 2 diabetes. Lastly, VK0214, another orally administered TRß selective agonist, is being developed for X-linked adrenoleukodystrophy. Established in 2012, Viking Therapeutics maintains its corporate headquarters in San Diego, California.
Similar biotech company
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Biotechnology
Cirius Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Grand Rapids, Michigan, focused on developing innovative therapies for metabolic and liver diseases.
Biotechnology
Rezo Therapeutics, Inc. is a biotechnology company headquartered in South San Francisco, California, that integrates proteomics, genetics, and structural biology for drug discovery and development.
Similar biotech company
Iterion Therapeutics is a clinical-stage biopharmaceutical company headquartered in Houston, Texas. Founded in 2015, the company is dedicated to revolutionizing healthcare through novel drug discovery and innovation.
Similar biotech company
Keros Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutics targeting the transforming growth factor-beta (TGF-ß) superfamily of proteins. The company focuses on creating treatments for patients with hematological and neuromuscular disorders linked to dysfunctional protein signaling.
Biotechnology
Syntis Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to revolutionizing oral therapies for obesity and metabolic diseases.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Akero Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Akero Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →